Abstract
Response to two doses of a nucleoside-modified messenger ribonucleic acid (mRNA) vaccine was evaluated in a large solid-organ transplant program. mRNA COVID-19 vaccine was administered to transplant candidates and recipients who met study inclusion criteria. Qualitative anti-SARS-CoV-2 Spike Total Immunoglobulin (Ig) and IgG-specific assays, and a semi-quantitative test for anti-SARS-CoV-2 Spike protein IgG were measured in 241 (17.2%) transplant candidates and 1163 (82.8%) transplant recipients; 55.2% of whom were non-Hispanic White and 44.8% identified as another race. Transplant recipients were a median (IQR) of 3.2 (1.1, 6.8) years from transplantation. Response differed by transplant status: 96.0% versus 43.2% by the anti-SARS-CoV-2 Total Ig (candidates vs. recipients, respectively), 93.5% versus 11.6% by the anti-SARS-CoV-2 IgG assay, and 91.9% versus 30.1% by anti-spike titers after two doses of vaccine. Multivariable analysis revealed candidates had higher likelihood of response versus recipients (odds ratio [OR], 14.6; 95 %CI 2.19, 98.11; P =.02). A slightly lower response was demonstrated in older patients (OR.96; 95 %CI.94,.99; P =.002), patients taking antimetabolites (OR,.21; 95% CI.08,.51; P =.001). Vaccination prior to transplantation should be encouraged.
Original language | English (US) |
---|---|
Article number | e14600 |
Journal | Clinical Transplantation |
Volume | 36 |
Issue number | 5 |
Early online date | Jan 26 2022 |
DOIs | |
State | Published - May 2022 |
Keywords
- COVID-19 vaccines
- antibodies
- blood
- chronic
- end stage kidney disease
- end stage liver disease
- heart failure
- immunology
- organ transplantation
- prevention and control
- pulmonary disease
- vaccines
- viral
- Humans
- Immunoglobulin G
- Organ Transplantation
- Transplant Recipients
- SARS-CoV-2
- COVID-19/epidemiology
- Immunity, Humoral
- Antibodies, Viral
- BNT162 Vaccine
- COVID-19 Vaccines
- Aged
- RNA, Messenger
ASJC Scopus subject areas
- Transplantation